Valion Bio closed at $0.52 on Nov 4, down 2.60%, within 0.0% of its lowest close since Sep 11. Volume of 99.2K shares was 0.06× its 20-day average (below normal).
Split-adjusted performance: -78.3% over one month.
Short interest was 115.5K shares at the Oct 15 settlement, up 31.3% from the prior report (9.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| VBIOValion Bio | $0.5171 | −2.60% | — | — | — | — | $1.1M | |
| JAGXJaguar Health | $0.4988 | −10.53% | −97.6% | −58.9% | −1036.8% | — | $1.2M | Compare |
| MTNBMatinas BioPharma Holdings | $1.19 | +4.39% | −88.3% | — | — | — | $1.2M | Compare |
| ARTLArtelo Biosciences | $2.27 | −5.42% | −90.9% | — | — | — | $1.2M | Compare |
| NXTSNexentis Technologies | $0.5550 | −2.46% | — | — | — | — | $806.6K | Compare |
| GOVXGeoVax Labs, Inc. New | $0.1680 | +2.38% | −89.8% | −100.0% | — | — | $1.5M | Compare |
| ELABPMGC Holdings | $1.92 | −1.03% | −91.0% | — | −225.1% | — | $1.6M | Compare |
| DCOYDecoy Therapeutics | $1.14 | +2.70% | −81.0% | — | −1042.8% | — | $746.9K | Compare |
| KPTIKaryopharm Therapeutics | $0.0729 | −17.44% | −99.2% | −11.9% | −200.5% | — | $1.7M | Compare |
No recent articles focused on Valion Bio.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
